CMS has named 15 additional prescription drugs, including diabetes medication Ozempic, for price negotiations under the Inflation Reduction Act. This marks the second round of negotiations aimed at reducing drug costs for Medicare beneficiaries.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
